This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
HDAC2 / Histone deacetylase 2 · IHC design guide
Design Immunohistochemistry for HDAC2
Plan paraffin-section HDAC2 staining around the general nuclear pattern and cytoplasmic staining seen in several tissues (HPA tissue IHC). Start the catalog antibody at 2–5 μg/mL and assess chromogenic staining across consistently fixed sections (datasheet A00325-3; standard IHC practice).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
HDAC2 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Predominantly nuclear; cytoplasmic in some tissues (HPA tissue IHC) | |
| Staining pattern | General nuclear staining, with cytoplasm in several tissues (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A00325-3) | |
| Positive control | Adipose tissue+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation conditions consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Staining and RNA expression have medium consistency (HPA tissue IHC) | |
| Regulation | No specific expression regulator reported (UniProt) | |
| Isoform / epitope | 2 isoforms; epitope coverage is unspecified (UniProt) |
Section 1
Recommended HDAC2 IHC & IF Protocols
The catalog antibody uses EDTA retrieval (datasheet A00325-3). The two published paraffin IHC protocols below use citrate retrieval (PMC12516541; PMC8572779).
| Sample | Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A00325-3) |
| Fixation | Image fixative and duration unreported (datasheet A00325-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A00325-3); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A00325-3) |
| Primary antibody | Rabbit anti-HDAC2, 2-5μg/ml (datasheet A00325-3) |
| Primary incubation | Overnight at 4 °C (datasheet A00325-3) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A00325-3) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | HDAC2-positive staining in adipocytes of adipose tissue (HPA tissue IHC: High). HPA tissue profile: General nuclear expression, accompanied by cytoplasmic expression in several tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval for the catalog antibody (datasheet A00325-3). Citrate retrieval is a published alternative (PMC12516541; PMC8572779).
Section 2
What Is the Expected HDAC2 Staining Pattern?
HDAC2 should stain nuclei across many cell types, with cytoplasmic staining in several tissues (HPA tissue IHC: Supported; medium consistency with RNA). Nucleoplasmic localization is independently supported by ICC-IF (HPA subcellular). Nuclear staining fits its chromatin-associated function and nuclear localization; cytoplasmic localization is also annotated (UniProt Q92769). HDAC2 has no transmembrane segment, so a membrane-restricted pattern is unexpected (UniProt Q92769 topology).
| Nuclear staining in adipocytes, marrow hematopoietic cells, or bronchial respiratory epithelium. | These cell populations have high IHC staining in the HPA record (HPA tissue IHC). Judge the result by the stained cells and their compartment, alongside the section controls; HPA reports general nuclear expression, with cytoplasmic staining in several tissues (HPA tissue IHC). |
| Predominantly membrane staining, with little or no nuclear signal. | A membrane-restricted pattern conflicts with supported nucleoplasmic localization and the absence of a transmembrane segment (HPA subcellular; UniProt Q92769 topology). Check morphology and controls, then investigate nonspecific staining or detection artefact before assigning this signal to HDAC2 (general IHC practice). |
| Strong staining in an unexpected cell population, especially without nuclear staining in expected cells. | Consider antibody cross-reactivity or endogenous detection activity, but do not infer either from one field (general IHC practice). HDAC2 is widely expressed, and HPA reports cytoplasmic expression in several tissues, so an unfamiliar positive cell type alone does not establish an artefact (UniProt Q92769; HPA tissue IHC). |
| Diffuse color over nuclei, cytoplasm, and spaces between cells. | A poorly separated signal is difficult to score as HDAC2 localization (general IHC practice). Compare a no-primary control and assess blocking, washing, and chromogen development; diffuse staining alone cannot establish target expression (general IHC practice). |
| No staining in a section expected to contain strongly positive cells. | First check tissue identity and the positive control, then review the IHC workflow (general IHC practice). HPA records high staining in bone marrow hematopoietic cells and adipocytes, but its tissue IHC reliability is Supported with medium RNA agreement; a blank section alone cannot establish HDAC2 absence (HPA tissue IHC). |
💡Expected HDAC2 appearanceCall a result consistent with HDAC2 when the expected cells show clear, predominantly nuclear staining—potentially with cytoplasmic signal in some tissues—and treat membrane-only or diffuse, control-matched color as suspect (HPA tissue IHC; HPA subcellular; UniProt Q92769 topology; general IHC practice).
| Compartment and function | HPA reports general nuclear IHC staining and supported nucleoplasmic ICC-IF localization (HPA tissue IHC; HPA subcellular). HDAC2 acts in chromatin-associated deacetylase complexes, supporting a nuclear expectation; UniProt also annotates cytoplasm, so cytoplasmic signal needs context rather than automatic rejection (UniProt Q92769). |
| Tissue and cell context | High staining is reported in adipocytes, marrow hematopoietic cells, bronchial respiratory epithelium, and several other listed populations; liver cholangiocytes are listed as low (HPA tissue IHC). Use these as relative interpretation anchors, not as proof that all other cells must be negative (HPA tissue IHC; UniProt Q92769: widely expressed). |
| Antibody evidence | Two listed antibodies, HPA011727 and CAB005054, have Supported IHC status (HPA antibodies). That status supports using HPA patterns as a reference, while the tissue profile has only medium consistency with RNA; it does not validate every signal from a different catalog antibody or establish identical staining across preparations (HPA tissue IHC; general IHC practice). |
| Protein forms and epitope claims | UniProt annotates two isoforms, a single chain spanning residues 1–488, no signal peptide or propeptide, and no transmembrane segment (UniProt Q92769). Without an antibody epitope map, these facts cannot establish which isoforms the catalog antibody detects or predict an isoform-specific staining pattern (UniProt Q92769; general IHC practice). |
| Retrieval and detection | Target-specific fixation effects are not established by the supplied assay evidence. Verify with a matched IHC source before attributing a result to fixation. |
| IF/ICC Q&A | Q: Where should HDAC2 appear in IF/ICC? A: Primarily in the nucleoplasm, which HPA marks as supported; UniProt also annotates cytoplasm (HPA subcellular; UniProt Q92769). Use the separate IF/ICC guide for that application's workflow; the ICC-IF localization record does not supply a paraffin IHC protocol (HPA subcellular). |
| Situation | Likely cause | Next action |
|---|---|---|
| Nuclei are blank in a known-positive control. | The staining run, tissue identity, or antibody performance may need review; one blank section cannot establish biological absence (general IHC practice). | Verify the control contains a listed high-staining population, then inspect the run's retrieval, primary antibody, detection, and counterstain steps (HPA tissue IHC; general IHC practice). |
| Color is strongest at cell membranes. | Membrane-restricted staining does not fit the supported nucleoplasmic pattern or UniProt topology (HPA subcellular; UniProt Q92769). | Compare a no-primary control, inspect section morphology, and reassess antibody-specific and detection-related background before scoring those cells positive (general IHC practice). |
| Cytoplasmic color accompanies nuclear staining. | Cytoplasmic HDAC2 is annotated, and HPA observes cytoplasmic IHC staining in several tissues (UniProt Q92769; HPA tissue IHC). | Score nuclear and cytoplasmic compartments separately, compare with controls, and describe the observed distribution; avoid calling the cytoplasmic component artefactual solely because it is extranuclear (general IHC practice). |
| Unexpected cells stain more strongly than the anticipated population. | The pattern could reflect broad expression, cross-reactivity, or endogenous detection activity; the image alone cannot distinguish them (UniProt Q92769; general IHC practice). | Check tissue identity and cell morphology, compare HPA's cell-specific examples, and use a no-primary control to assess detection-derived color (HPA tissue IHC; general IHC practice). |
| Diffuse background obscures nuclear boundaries. | Background may arise from incomplete blocking, washing, or detection control; the supplied sources do not identify an HDAC2-specific cause (general IHC practice). | Review the no-primary control, blocking and wash steps, and chromogen development; score only clearly resolved cellular signal (general IHC practice). |
| A low-staining population appears intensely positive. | HPA lists liver cholangiocytes as low, while its overall tissue IHC profile has medium consistency with RNA (HPA tissue IHC). | Confirm the cells and compare the same run's controls before treating the discrepancy as biology; report the observed pattern and its uncertainty (HPA tissue IHC; general IHC practice). |
Experiment evidence
IHC & IF images showing HDAC2 staining
A00325-3 · IHCIHC analysis of HDAC2 using anti-HDAC2 antibody (A00325-3). HDAC2 was detected in a paraffin-embedded section of human breast cancer tissue.
A00325-3 · IHCIHC analysis of HDAC2 using anti-HDAC2 antibody (A00325-3). HDAC2 was detected in a paraffin-embedded section of human colon cancer tissue.
A00325-3 · IFIF analysis of HDAC2 using anti-HDAC2 antibody (A00325-3). HDAC2 was detected in an immunocytochemical section of Caco-2 cells. Enzyme antig
M00325-1 · IHCIHC analysis of HDAC2 using anti-HDAC2 antibody (M00325-1). HDAC2 was detected in a paraffin-embedded section of human breast cancer tissue.
M00325-3 · IHCMouse colon was stained with Anti-HDAC2 rabbit antibody
M00325-3 · IHCRat spleen was stained with Anti-HDAC2 rabbit antibody
A00325-1 · IHCImmunohistochemistry of HDAC2 in rat testis tissue with HDAC2 antibody at 5 μg/mL.
A00325-1 · IFImmunofluorescence of HDAC2 in rat testis tissue with HDAC2 antibody at 20 μg/mL.
A00325-2 · IHCHDAC2 Antibody (Center) (Cat. #A00325-2) immunohistochemistry analysis in formalin fixed and paraffin embedded human lung carcinoma followed
A00325-2 · IFFluorescent confocal image of Hela cell stained with HDAC2 Antibody (Center). Hela cells were fixed with 4% PFA (20 min), permeabilized with
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000196591-HDAC2/tissue/cerebral+cortex#imid_1985520
HPA · Salivary glandHuman Protein Atlas IHC, Salivary gland. Source: https://www.proteinatlas.org/ENSG00000196591-HDAC2/tissue/salivary+gland#imid_1985476
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000196591-HDAC2/tissue/colon#imid_1985462
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000196591-HDAC2/tissue/liver#imid_1985463
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA011727; green = HDAC2, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA011727; green = HDAC2, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for HDAC2 IHC & IF
🧪Run bone marrow first: hematopoietic cells should show nuclear staining (HPA: High in hematopoietic cells; UniProt Q92769: nucleus). HPA detects HDAC2 in all 45 scored tissues, so there is no HPA negative tissue; use no-primary and isotype controls, and treat any cells lacking nuclear DAB above background on the positive slide as provisional internal negatives rather than a validated negative cell type (HPA: no negative rows).
Positive control tissue: Adipose tissue (Adipocytes, HPA High)
Negative control tissue: None in HPA: HDAC2 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show HDAC2 in A-431, U-251MG, U2OS, KOLF2.1J, with annotated localisation: Nucleoplasm (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only slide, a control using rabbit IgG matched to the primary antibody’s clonality, and HDAC2-knockout material as a biological negative (selected IHC caption: rabbit primary). Quench endogenous peroxidase and check for residual DAB background in bone marrow, where hematopoietic cells are the intended positive population (HPA: High in bone marrow hematopoietic cells).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence, and the selected A00325-3 paraffin-section caption does not state a fixative. The caption uses heat-mediated EDTA retrieval at pH 8.0, but does not establish that retrieval is required for every specimen (selected IHC caption: EDTA pH 8.0). ICC-IF is feasible as a separate application with nucleoplasmic localization reported by HPA; the supplied evidence does not establish that IF or frozen sections are easier than paraffin IHC, and bone marrow peroxidase background requires checking (HPA: nucleoplasm supported; HPA: High in bone marrow hematopoietic cells).
HPA tissue IHC evidence for HDAC2
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: HDAC2 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced HDAC2 IHC Tips
Troubleshoot HDAC2 staining in paraffin sections by checking retrieval, nuclear localisation, controls and cell-specific scoring before interpreting chromogenic signal.
Which retrieval conditions should I try first for weak HDAC2 staining?
Start with heat-mediated retrieval in EDTA at pH 8.0 for paraffin sections (datasheet A00325-3). The catalog antibody produced a tissue-IHC image after that retrieval, followed by 2 μg/ml primary antibody overnight at 4°C (datasheet A00325-3). If nuclear staining is weak, compare retrieval heating and cooling conditions on adjacent sections while holding antibody concentration and detection constant (standard IHC practice). Excessive retrieval can damage section morphology or increase diffuse staining, so judge intensity alongside intact nuclei (standard IHC practice). Use a matched positive control and score nuclear signal before adopting a changed retrieval condition (HPA tissue IHC; standard IHC practice).
Could fixation explain absent or uneven HDAC2 staining?
Target-specific sensitivity of HDAC2 staining to fixation is unknown from the supplied evidence; the paraffin-section caption does not state its fixative (datasheet A00325-3). Record the actual fixative and fixation duration for each specimen, and compare similarly processed sections before changing antibody concentration (standard IHC practice). Check whether nuclei remain morphologically intact and whether a positive control stains after EDTA retrieval at pH 8.0 (datasheet A00325-3; standard IHC practice). If signal varies across a section, assess tissue preservation and section adhesion before attributing the pattern to HDAC2 biology (standard IHC practice). Do not infer fixation tolerance from the reported nuclear distribution or protein modifications (HPA tissue IHC; UniProt Q92769).
Should I accept cytoplasmic HDAC2 staining in a paraffin section?
Use nuclear staining as the principal localisation check: tissue IHC reports general nuclear expression, and cellular imaging supports nucleoplasmic localisation (HPA tissue IHC; HPA subcellular). Cytoplasmic staining can occur in several tissues, and UniProt also lists cytoplasmic localisation (HPA tissue IHC; UniProt Q92769). Compare nuclear and cytoplasmic signal separately in the same cell population, using the established 2 μg/ml overnight primary incubation as a starting reference (datasheet A00325-3; standard IHC practice). Diffuse cytoplasmic colour without convincing nuclei merits a check of background, retrieval and section integrity (standard IHC practice). HDAC2 has no annotated transmembrane segment, so a membrane-restricted pattern needs independent verification (UniProt Q92769 topology).
Can this stain distinguish HDAC2 isoforms or altered epitopes?
The record lists 2 HDAC2 isoforms, but the supplied tissue-IHC caption does not identify the antibody epitope or establish isoform selectivity (UniProt Q92769; datasheet A00325-3). Treat positive staining as antibody-reactive HDAC2 signal until epitope mapping or an independent specificity experiment resolves that question (standard IHC practice). HDAC2 has annotated acetylation, S-nitrosylation and phosphorylation sites, including phosphoserine at residue 394 (UniProt Q92769). Their effects on this antibody's staining are unreported, so do not explain a weak region by modification status alone (UniProt Q92769; datasheet A00325-3). Compare a second independently validated epitope or a suitable loss-of-target control if isoform or epitope interpretation is essential (standard IHC practice).
How should I cross-check an HDAC2 IHC pattern by multiplex IF?
Design IF as a separate validation experiment; the supplied 2 μg/ml overnight condition was documented for chromogenic tissue IHC, not IF (datasheet A00325-3). Pair HDAC2 with a cell-type marker relevant to the sampled tissue, such as a glial marker when examining glial cells, and confirm nuclear overlap with a nuclear counterstain (HPA tissue IHC; standard IF practice). Choose a spectrally separated, preferably longer-wavelength fluorophore after checking the specimen's autofluorescence and single-colour controls (standard IF practice). Because HDAC2 is nucleoplasmic and has no transmembrane segment, optimise permeabilisation for access to an intracellular nuclear epitope (HPA subcellular; UniProt Q92769 topology; standard IF practice). Do not transfer IF intensity thresholds directly to DAB scores (standard IHC/IF practice).
How can I separate weak nuclear HDAC2 from brown background?
Assess whether DAB is concentrated in intact nuclei and persists when staining conditions are reproduced on an adjacent section (HPA tissue IHC; standard IHC practice). The documented method used 10% goat serum blocking, 2 μg/ml primary antibody overnight at 4°C, and a peroxidase-linked secondary (datasheet A00325-3). Include a no-primary control and an appropriate peroxidase block to identify detection-related colour (standard IHC practice). If diffuse staining rises with stronger retrieval or antibody concentration, return to the documented EDTA pH 8.0 condition and compare sections processed together (datasheet A00325-3; standard IHC practice). Exclude tissue folds, damaged edges and pigment when judging faint positive nuclei (standard IHC practice).
What should I score when comparing HDAC2 across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and score nuclear HDAC2 separately from cytoplasmic colour, because the reported tissue pattern is generally nuclear with cytoplasmic expression in several tissues (HPA tissue IHC). For intensity-based comparisons, use a nuclear H-score calculated from the percentage of cells at each staining intensity; report the percentage of positive nuclei alongside it (standard IHC practice). For spatial questions, report positive nuclei per mm² of viable, evaluable tissue (standard IHC practice). Normalise counts to the number of eligible cells or measured tissue area, and apply one threshold across sections stained in the same run (standard IHC practice). Document compartment, cell-type selection and excluded regions so differences remain interpretable (standard IHC practice).
When is an apparent HDAC2-positive region likely to be artefact?
Give greatest weight to staining in intact nuclei within a defined cell population, consistent with general nuclear tissue expression and supported nucleoplasmic localisation (HPA tissue IHC; HPA subcellular). A purely membrane-restricted pattern is discordant with HDAC2's lack of an annotated transmembrane segment (UniProt Q92769 topology). Treat colour limited to section edges, folds, necrotic regions or a no-primary control as suspect, and check endogenous peroxidase before calling it positive (standard IHC practice). Cytoplasmic signal alone requires caution because cytoplasmic expression is reported in several tissues, yet the overall tissue pattern is nuclear (HPA tissue IHC). Confirm an unexpected cell population against matched controls and a reproducible nuclear pattern before interpreting biological differences (standard IHC practice).
Boster reagents
Best HDAC2 / Histone deacetylase 2 IHC Antibodies
The catalog shows HDAC2 IHC images in human, mouse, and rat tissues, plus IF images in human cells and rat testis (catalog image captions).
Real IHC data
Anti-HDAC2 Antibody ®
Cat # A00325-3
Real IHC data
Anti-HDAC2/Histone Deacetylase 2 Rabbit Monoclonal Antibody
Cat # M00325-1
Real IHC data
Anti-HDAC2 Rabbit Monoclonal Antibody
Cat # M00325-3
Real IHC data
Anti-Histone deacetylase 2 HDAC2 Antibody
Cat # A00325-1
Real IHC data
Anti-HDAC2 Antibody (Center)
Cat # A00325-2
A00325-3 shows IHC in human breast, colon, thyroid, and laryngeal tumors; M00325-1 shows human breast tumor; and M00325-3 shows mouse colon, rat spleen, and human tonsil (catalog IHC image captions). A00325-1 shows rat testis by IHC and IF, while A00325-2 shows human lung carcinoma by IHC and HeLa cells by IF (catalog image captions).
Which to pick: For paraffin tissue IHC, A00325-3 has four human tissue examples with EDTA retrieval and DAB detection; its IHC captions do not report the fixative (A00325-3 IHC image captions). For IF/ICC, A00325-3 has a Caco-2 cell IF example, while A00325-2 has a HeLa cell IF example (catalog IF image captions). For IHC across species, consider monoclonal M00325-3: its listed reactivity is human, mouse, and rat, with IHC images from each species (M00325-3 catalog reactivity and IHC image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q92769 (HDAC2_HUMAN, Histone deacetylase 2).
- Human Protein Atlas. HDAC2 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. HDAC2 subcellular location (ICC-IF): Localized to the nucleoplasm..
- Human Protein Atlas. HDAC2 antibody validation summary (2 antibodies).
- HDAC2 promotes malignant progression by the RBM47/NONO axis in medulloblastoma. Translational oncology 2025 — PMC12516541.
- The role of HDAC2 inhibition in cardioprotection against doxorubicin-induced myocardial injury. Frontiers in cardiovascular medicine 2025 — PMC11897267.
- Complex regulation of the regulator of synaptic plasticity histone deacetylase 2 in the rodent dorsal horn after peripheral injury. Journal of neurochemistry 2016 — PMC4982040.
- Histone deacetylase HDAC2 silencing prevents endometriosis by activating the HNF4A/ARID1A axis. Journal of cellular and molecular medicine 2021 — PMC8572779.
- PubMed PMID:8917507 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:14574404 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for HDAC2 (Histone deacetylase 2). Expected localisation Predominantly nuclear; cytoplasmic in some tissues (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A00325-3). Validated IHC antibody: A00325-3 at 2-5μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adipose tissue (Adipocytes); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A00325-3); 2. Fixation: Image fixative and duration unreported (datasheet A00325-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A00325-3); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A00325-3); 8. Primary antibody: Rabbit anti-HDAC2, 2-5μg/ml (datasheet A00325-3); 9. Primary incubation: Overnight at 4 °C (datasheet A00325-3). Watch for: Fixation: Keep fixation conditions consistent across sections (standard IHC practice; not target-specific); Caveat: Staining and RNA expression have medium consistency (HPA tissue IHC); Isoform / epitope: 2 isoforms; epitope coverage is unspecified (UniProt); Regulation: No specific expression regulator reported (UniProt). Evidence: UniProt Q92769, HPA tissue IHC · Supported, HPA ICC-IF · nucleoplasm., Datasheet A00325-3, PMC12516541, PMC8572779. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/HDAC2/immunohistochemistry-ihc-guide.